A slight improvement of OS for non-APC-mutated patients with immunotherapy was also observed compared to APC-mutated patients who treated with the same immunotherapy in LCC, although not significant due to the small sample size (Figure 9C), suggesting non-APC mutation can be considered as a biomarker for immunotherapy efficacy in both LCC and RCC. This evidence concerns the gene APC and leukoencephalopathy with calcifications and cysts.